Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment

Abstract

IntroductionHealth-related quality of life (HRQoL) has emerged as an important consideration in the care of patients with chronic hepatitis B (CHB). However, whether benefits from the improved HRQoL that occurs after antiviral treatment or drug discontinuation outweigh the risks of viral relapse is an unanswered question. The aim of this study was to evaluate the HRQoL among patients with CHB during antiviral treatment and withdrawal of treatment.Patients and methodsThere were 102 patients who met the enrollment criteria with 54 patients in the treatment group and 48 patients in the discontinuation group. Sociodemographic information was collected. The 36-Item Short-Form Health Survey (SF-36), European Quality of Life-5 Dimensions, and Beck Depression Inventory (BDI) were adopted to evaluate life quality and mental health.ResultsIn the treatment group, SF-36 showed that the physical functions were significantly increased. In the discontination group, the psychological functions showed improvement. A multivariate regression analysis indicated that baseline SF-36 score was a predictor for improvement in HRQoL (odds ratio =1.17, P=0.003) and baseline BDI score was a factor for remission of depression (odds ratio =0.75, P=0.005) after medical intervention. When the cutoff value of SF-36 score was set at 79.5, the sensitivity and specificity to predict improvement in HRQoL were 82.8% and 74.0%, respectively. When the cutoff value of BDI was found as 8.5, the sensitivity and specificity to predict alleviation of depression were 58.6%, and 76.0%, respectively.ConclusionAntiviral treatment benefits the physical health of the patients with CHB, while conferring no obvious improvement in their psychological condition. Improved psychological interventions for patients with CHB, especially for those with lower baseline SF-36 scores and higher BDI scores, may improve their quality of life.

Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma

“…But the mechanisms of carcinogenesis are different compared with NBNC-HCC [20,22]. HBV is a DNA virus that causes malignant transformation of hepatocytes mainly through gene integration into chromosomes and activation of oncogenes [25][26][27][28]. The mechanism of NBNC-HCC is still unclear, and metabolic factors may be an important factor [21,22].…”

Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome

“…It is well established that CHB, NAFLD, and MetS lead to the development of liver fibrosis, cirrhosis, and HCC. [22][23][24] A prospective study from Taiwan indicated that a high BMI at baseline correlated with the incidence of liver cirrhosis and HCC. 25 In our study, we found that CHB patients with MetS components had accelerated rates of liver fibrosis.…”

Dynamic Changes of the Aspartate Aminotransferase‐to‐Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment

“…These agents are aimed at inhibiting the reverse transcription of pregenomic RNA with suppression of HBV replication . However, complete eradication of HBV infection is difficult because of the nature of HBV replication . Hence, patients have required regular follow‐ups to monitor their liver condition during antiviral treatment, especially when they progressed into liver fibrosis.…”

“…24 However, complete eradication of HBV infection is difficult because of the nature of HBV replication. [25][26][27] Hence, patients have required regular follow-ups to monitor their liver condition during antiviral treatment, especially when they progressed into liver fibrosis. Liver biopsy has been recommended as the reference standard for evaluating the degree of liver fibrosis.…”